Navigation Links
GW researcher reveals how amphibians crossed continents
Date:8/4/2014

movement can explain the majority of patterns in the distribution of extant species of amphibians.

Dr. Pyron also found that dispersal during the Cenozoic Era (66 million years ago to the present), likely across land bridges or short distances across oceans, also contributed to their distribution.

Given their ancient origin, it is unsurprising that the history of amphibians is a mixture of both vicariance and dispersal. But the third and final distribution pattern that Dr. Pyron notes in his study was an unexpected finding.

Past studies have assumed that long-distance over water dispersal was essentially impossible for amphibians due to salt intolerance. However, when Dr. Pyron began completing his analysis, he noticed a number of cases of distribution that could not be explained by old age.

For instance, one group of frogs found in Australia and New Guinea (pelodryadine hylids) that originated around 61 to 52 million years ago is deeply nested within a group of amphibians that exist only in South America. By the time pelodryadines originated, all major continental landmasses occupied their present-day positions, with South America and Australia long separated from Antarctica.

"They're 120 million years too late to have walked to Australia," Dr. Pyron said.

So how could this group of South American amphibians be related to frogs on the other side of the world?

"You wouldn't think that frogs would be able to swim all the way there, but that seems like one of the more likely explanations for how you could have such a young group nested within South America and have it somehow get to this other continent," Dr. Pyron said.

In his study, Dr. Pyron points two other instances of long-distance oceanic dispersal.

"What you have is this mixture of processes. You have vicariance, which over 300 million years has put certain groups in Africa, some in Australia and others in South America," Dr. Pyr
'/>"/>

Contact: Kurtis Hiatt
kkhiatt@gwu.edu
202-994-1849
George Washington University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers to track effects of revolutionary new medicines
2. UMD researchers develop tool to better visualize, analyze human genomic data
3. UC Davis memory researcher wins Pentagon grant
4. Gulf oil spill researcher: Bacteria ate some toxins, but worst remain
5. Monash researcher receives Antarctic science award
6. New method provides researchers with efficient tool for tagging proteins
7. Researchers uncover secrets of internal cell fine-tuning
8. Researcher using next-generation sequencing to rapidly identify pathogens
9. GW researcher receives grant to answer the how and why of autism during development
10. University of Houston researcher publishes textbook on tissue engineering
11. Whitehead Institute researchers create naïve pluripotent human embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... COLUMBUS, Ohio Very few athletic trainers associated with ... were following best practice standards for managing asthma among ... athletes with asthma, the dangers of the condition can ... severe to be incapacitating, or deadly. The lead report ...
... and inanimate phenomena may have more in common than previously ... University engineer Adrian Bejan and Penn State biologist James Marden. ... theory that flow systems from animal locomotion to the ... and minimize imperfections. Flows evolve to reduce friction or other ...
... Conan Doyle,s account of an isolated community of dinosaurs that ... no less appeal now than it did when it was ... recreate the lost world of dinosaurs, but today the fiction ... suggests that dinosaur bones from the Ojo Alamo Sandstone in ...
Cached Biology News:Athletes with asthma need more help from their team trainers 2Unifying the animate and the inanimate designs of nature 2Evidence of the 'Lost World' -- did dinosaurs survive the end Cretaceous extinctions? 2
(Date:8/3/2015)... RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical ... cell therapies, announced today that RepliCel,s CEO, David Hall ... Minneapolis, Minnesota on August 5 th ... RepliCel,s 18-month milestones including CE Mark for its RCI-02 dermal ... data from both RCT-01 (tendon) and RCS-01 (skin) clinical trials ...
(Date:7/31/2015)... 31, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has filed its Annual ... Exchange Commission. The filed Form 20-F includes audited financial ... The Form 20-F can be accessed by visiting the ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
Breaking Biology Technology:RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: ... its fourth quarter and fiscal year 2008 on December 11, 2008, ... at 4:45 p.m. ET Martek will conduct a conference call to ... to the call live via webcast by visiting Martek,s web site ...
... Early to Mid-2009 , , ... the proprietary products division of Par Pharmaceutical Companies, Inc. ... development partner, MonoSol Rx, reported the successful completion of ... of ondansetron. The ondansetron thin film product is being ...
... (BCI), a,biopharmaceutical company utilizing its platform technology to ... new neurons for the treatment of,central nervous system ... Thompson to its board of directors. Thompson is ... tenure at Eli Lilly and Co. where he,focused ...
Cached Biology Technology:Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 2Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 4BrainCells Inc. Appoints David E. Thompson to Its Board of Directors 2BrainCells Inc. Appoints David E. Thompson to Its Board of Directors 3